Whitehawk Therapeutics (WHWK) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 10, 2026.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting or until successors are qualified.

• Advisory vote to approve executive compensation as disclosed in the 2025 Summary Compensation Table.

• Ratification of BDO USA, P.C. as independent registered accounting firm for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Nominees for Class III directors are Behzad Aghazadeh, Ph.D., Richard Maroun, and Emma Reeve.